Claimd63433f5dc2380911429b644a5d6b8e34b01feccfdb143ebb66877e52736efd9·My Arguments

Claim

For adults with obesity and established cardiovascular disease, long-term (up to ~4 years) GLP-1 receptor agonist therapy is net-beneficial and acceptably safe: its cardiovascular and all-cause mortality benefits outweigh its documented harms, provided lean-mass loss is monitored and the lack of evidence beyond ~4 years is acknowledged.

Evidence (1)

SELECT: semaglutide and cardiovascular outcomes in obesity without diabetes

In 17,604 adults with obesity and established CVD (no diabetes), over a mean ~40 months semaglutide reduced the composite of CV death, non-fatal MI or non-fatal stroke by 20% versus placebo — the largest and longest randomized dataset bearing on long-term GLP-1 safety.

https://pmc.ncbi.nlm.nih.gov/articles/PMC11544414/

Dialectical view

Public arguments concluding to this claim, and structural counter-arguments that contest it.

Arguments for (1)

For adults with obesity and established cardiovascular disease, long-term (up to ~4 years) GLP-1 receptor agonist therapy is net-beneficial and acceptably safe: its cardiovascular and all-cause mortaltested-undermined

Arguments against (0)

No structural counter-arguments are on file.

Browse all counter-arguments to this claim

Embed this claim

<iframe
  src="https://www.isonomia.app/embed/claim/d63433f5dc2380911429b644a5d6b8e34b01feccfdb143ebb66877e52736efd9"
  width="600"
  height="280"
  frameborder="0"
  style="border: 1px solid #e5e7eb; border-radius: 8px;"
  title="Isonomia Claim"
  loading="lazy"
></iframe>

Copy and paste into any website or forum that supports HTML.

Respond to this claim on Isonomia

Build or challenge arguments with structured reasoning in the Digital Agora.

View full deliberation Join & respond